Can You Take Antibiotics While on Immunotherapy?

Antibiotics are not strictly prohibited during immunotherapy, but a substantial body of evidence shows they can blunt its effectiveness. Pooled data across dozens of studies link antibiotic use around the start of immune checkpoint inhibitor (ICI) treatment with shorter survival times, and the mechanism centers on disruption of the gut bacteria that help the immune system recognize and attack tumors. Whether the trade-off makes sense depends on the infection you’re facing, the timing, and the type of antibiotic your doctor prescribes.

How Much Do Antibiotics Reduce Immunotherapy’s Effectiveness?

The signal is consistent and not subtle. A systematic review and meta-analysis pooling results across cancer types found that patients who took antibiotics had roughly 60 percent higher risk of death and 45 percent higher risk of disease progression compared to those who did not, after adjusting for other factors.¹ In lung cancer specifically, a separate meta-analysis found that antibiotic-exposed patients lost more than six months of median overall survival compared to unexposed patients.²

These are observational findings, not randomized trials, which means some of the association could be explained by confounding. Patients who need antibiotics are often sicker to begin with: they may have infections that signal a weaker immune system or more advanced disease. Researchers have tried to account for this statistically, and the association persists after adjustment, but it’s worth keeping in mind that the true effect of antibiotics alone is probably somewhat smaller than the raw numbers suggest. Still, the consistency across study after study and cancer type after cancer type has shifted the conversation in oncology from “probably fine” to “avoid if you can.”³

The Timing Window That Matters Most

Not all antibiotic exposure carries equal risk. The data consistently point to a critical period running from about two months before immunotherapy begins through the first two months of treatment. A meta-analysis focused on this window confirmed that antibiotics given within 60 days before or after ICI initiation were most strongly associated with worse outcomes.⁴

A study that separated “prior” antibiotics (given before immunotherapy started) from “concurrent” antibiotics (given during treatment) found strikingly different results. Patients who received antibiotics before starting ICI therapy had a median overall survival of just two months, compared to 26 months for those who did not. Concurrent antibiotics during treatment showed no significant survival difference.⁵ The interpretation here is that arriving at your first immunotherapy infusion with an already-disrupted gut microbiome is worse than encountering antibiotics later, presumably because the immune system’s initial priming against the tumor depends heavily on the microbial signals present at that early stage.

That said, smaller studies have found trends toward worse outcomes with concurrent antibiotics too, even if the results didn’t reach statistical significance. One analysis of 256 patients showed a 35 percent worse overall survival among antibiotic users, though the confidence interval was wide.⁶ The safest interpretation is that any antibiotic use around immunotherapy carries some risk, but the window right before and at the beginning of treatment is where the damage seems hardest to undo.

Why Gut Bacteria Matter for Immunotherapy

Immune checkpoint inhibitors work by releasing the brakes on your immune system so it can attack cancer cells. But the immune system doesn’t do this in a vacuum. Research has shown that the composition and diversity of bacteria in your gut play a surprisingly large role in how vigorously your immune cells respond to these drugs. In a study of lung cancer patients receiving anti-PD-1 therapy, those who responded well to treatment had higher gut microbiome diversity at the start, and that diversity stayed stable throughout treatment. Patients with diverse gut bacteria also had more memory immune cells and natural killer cells circulating in their blood.⁷

The connection works through several pathways. Certain gut bacteria produce metabolites, particularly short-chain fatty acids like butyrate, that can activate immune cells involved in killing tumors. Other bacteria appear to train the immune system through molecular mimicry, where bacterial surface proteins resemble tumor proteins closely enough to keep immune cells primed. Antibiotics, especially broad-spectrum ones, wipe out many of these beneficial populations at once, reducing both the diversity and the metabolic output that immunotherapy depends on.⁸

Preclinical work in mice has confirmed the mechanism in a more controlled setting. Antibiotic-treated mice responded worse to cyclophosphamide-based chemoimmunotherapy and to adoptively transferred tumor-specific T cells. Interestingly, CAR-T cell therapy (which uses engineered immune cells rather than relying on the body’s own immune activation) was not affected by antibiotics, which reinforces the idea that it’s the endogenous immune priming step that antibiotics disrupt.⁹

Which Antibiotic Classes Are Worst

Not all antibiotics appear equally harmful, though the evidence here is less settled. A melanoma study found that penicillins carried the strongest survival detriment, followed by cephalosporins and fluoroquinolones. Narrower-spectrum agents like macrolides, tetracyclines, and trimethoprim-sulfamethoxazole were not associated with worse survival, though the number of patients taking these drugs was small.¹⁰

In lung cancer, the picture is somewhat different. One study found that beta-lactams (particularly penicillins) significantly shortened both overall survival and progression-free survival, while quinolones alone did not reach significance. The worst outcomes were in patients who received both drug classes together.¹¹ Meanwhile, a study in Asian cancer patients found the opposite pattern for fluoroquinolones, with those patients having a median survival of about four months compared to roughly twelve months for patients on other broad-spectrum drugs.¹²

The conflicting results likely reflect differences in patient populations, cancer types, and the specific bacteria each drug class tends to eliminate. What’s clear is that broad-spectrum antibiotics, the kind that wipe out the widest range of gut bacteria, are consistently more problematic than narrow-spectrum ones. When antibiotics are truly necessary, choosing the narrowest effective agent is a sensible strategy.

Does the Cancer Type Change the Risk?

The antibiotic penalty shows up across virtually every solid tumor studied, but its magnitude varies. Kidney cancer patients appear particularly vulnerable. In one landmark study, antibiotic-exposed patients with renal cell carcinoma had a 75 percent rate of primary disease progression on immunotherapy, versus 22 percent for unexposed patients. Their median progression-free survival was 1.9 months versus 7.4 months. Lung cancer patients in the same study also fared worse with antibiotics, though the gap in progression rates was smaller.¹³

A comparative analysis across three tumor types found that the specific antibiotic classes driving the association differed by cancer. In lung cancer, broad-spectrum anti-anaerobic agents and vancomycin-type drugs were the main offenders. In kidney cancer, penicillins and early-generation cephalosporins stood out. In acute myeloid leukemia patients receiving chemotherapy rather than immunotherapy, antibiotics did not affect outcomes at all, suggesting the gut-immune axis matters primarily when the treatment itself relies on immune activation.¹⁴

Antibiotics May Also Increase Side Effects

Beyond reducing effectiveness, antibiotic use appears to raise the risk of immune-related adverse events, the side effects that occur when an unleashed immune system attacks healthy tissue alongside the tumor. A study combining institutional data with two large pharmacovigilance databases found that antibiotic-treated patients were roughly twice as likely to develop these side effects. Lung cancer patients had an even higher risk, around three times the odds.¹⁵

Immune-mediated colitis, an inflammation of the colon that is one of the more common and serious immunotherapy side effects, was specifically elevated. In melanoma patients, those who had taken antibiotics were about twice as likely to develop colitis severe enough to need intravenous steroids within a year of starting treatment.¹⁰ The mechanism likely involves reduced microbial diversity leaving the gut lining more susceptible to immune attack, a troubling irony given that antibiotics are sometimes prescribed specifically for gastrointestinal symptoms.

Proton Pump Inhibitors Make It Worse

Acid-suppressing drugs like omeprazole and pantoprazole, commonly prescribed for heartburn and stomach protection, also alter gut bacteria. When patients take both a proton pump inhibitor (PPI) and antibiotics around the time of immunotherapy, the negative association with outcomes appears to compound. A post-hoc analysis of the large PACIFIC trial in stage III lung cancer found a graded pattern: patients exposed to neither drug class had the best outcomes, those exposed to one class had intermediate outcomes, and those exposed to both had the shortest progression-free and overall survival.¹⁶ The same stepped pattern appeared in head and neck cancer patients treated with nivolumab.¹⁷

This matters practically because many cancer patients are on PPIs almost by default, either for genuine reflux or as a prophylactic measure during treatment. If you’re starting immunotherapy, it’s worth discussing with your oncologist whether a PPI you’re currently taking is truly necessary or could be stepped down.

Can Probiotics or Diet Help Protect the Microbiome?

Given that the antibiotic problem is fundamentally a microbiome problem, researchers have naturally asked whether probiotics or dietary changes can offset the damage. The evidence is mixed and evolving, with some surprising wrinkles.

For patients who do end up needing antibiotics, probiotics may partially restore the benefit. A meta-analysis focused on lung cancer patients found that those who took probiotics alongside antibiotics had roughly half the risk of death and disease progression compared to antibiotic users who skipped probiotics.¹⁸ A study of over 500 lung cancer patients confirmed this: probiotic use restored outcomes in antibiotic-exposed patients to levels comparable with patients who received neither antibiotics nor probiotics. Among patients not on antibiotics, probiotics helped only when taken for more than 15 days, and the benefit tracked with enrichment of specific bacterial species like Bifidobacterium.¹⁹

However, the probiotic story has a counterintuitive twist. A study of 128 melanoma patients on immunotherapy found that the best outcomes were in patients who ate a high-fiber diet but did not take commercial probiotics. In mouse models from the same research group, probiotic supplementation actually impaired anti-PD-1 treatment response and reduced the frequency of tumor-killing T cells.²⁰ The difference may come down to what probiotics are being used, in what cancer context, and whether the patient’s existing microbiome already has adequate diversity. Commercial probiotic supplements typically contain only a handful of bacterial strains, which could crowd out the natural diversity that immunotherapy depends on.

Dietary fiber, by contrast, has a more straightforward positive signal. High-fiber diets feed a broad range of gut bacteria, promoting the production of short-chain fatty acids that activate immune cells involved in tumor killing. A scoping review of the evidence found that higher fiber intake from whole foods was consistently associated with better immunotherapy responses, primarily in melanoma patients studied so far.²¹ Mediterranean-style diets rich in plants, whole grains, and legumes have emerged as a practical recommendation in narrative reviews of the field.²²

Fecal Microbiota Transplantation as a Rescue Strategy

The most dramatic approach to restoring gut bacteria after antibiotic damage is fecal microbiota transplantation (FMT), in which stool from a healthy donor is introduced into the patient’s gut. In mouse models, FMT from patients who had responded to immunotherapy made recipient mice more responsive to anti-PD-1 treatment and increased tumor-infiltrating immune cells. Transplanting stool from non-responders had the opposite effect.²³

In human trials, the results are early but encouraging. A meta-analysis of clinical studies found that FMT combined with checkpoint inhibitors achieved an overall response rate of about 30 percent, which is meaningful considering that many of these patients had already failed prior immunotherapy.²⁴ FMT remains experimental and is not yet standard care, but it represents the clearest proof of concept that the microbiome is genuinely driving the antibiotic-immunotherapy interaction rather than merely tagging along.

Practical Guidance When You Need an Antibiotic

None of this means you should refuse antibiotics if you have a serious infection during immunotherapy. Cancer patients are often immunocompromised, and untreated bacterial infections can be life-threatening. The goal is smarter prescribing, not no prescribing. Oncology guidelines increasingly emphasize antibiotic stewardship: using the narrowest-spectrum agent that will treat the infection, avoiding prophylactic antibiotics when the clinical benefit is unclear, and being especially cautious in the weeks leading up to and immediately following the start of immunotherapy.³

If you’re scheduled to begin immunotherapy, it’s reasonable to ask your care team a few specific questions. Is the antibiotic being prescribed for a confirmed bacterial infection, or is it precautionary? Could a narrower-spectrum drug work instead of a broad-spectrum one? Is it possible to delay the immunotherapy start date until you’ve recovered from both the infection and the antibiotic course? And are there any other gut-disrupting medications, like PPIs, that could be safely reduced or stopped? These conversations don’t second-guess your doctor so much as flag a dimension of care that oncology teams are increasingly attentive to.

The Short-Chain Fatty Acid Wrinkle

One complexity worth noting is that the relationship between microbial metabolites and cancer treatment is not always straightforward. Short-chain fatty acids, especially butyrate, are generally described as immune-activating and beneficial. But in the context of radiation therapy, research has found the opposite: butyrate accumulating inside tumors actually suppressed the immune signaling pathway that radiation depends on, and depleting butyrate-producing bacteria with targeted antibiotics improved radiation outcomes in mice.²⁵ This doesn’t undermine the checkpoint inhibitor story, where the evidence for microbiome preservation is strong. But it does illustrate that the immune system’s interaction with gut bacteria is context-dependent, and blanket rules about “good” and “bad” bacteria oversimplify what’s happening. As immunotherapy combines with other modalities like radiation and chemotherapy, the optimal microbiome state for each combination may turn out to be different.